[Pharmacological studies with 1-isopropylamino-3-(o-allyloxyphenoxy)-2-propanol-hydrochloride, an adrenergic beta-receptor blocking agent].
D000605:Amino Alcohols / Q000494:pharmacology*; D000779:Anesthetics, Local; D000818:Animals; D001775:Blood Circulation / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002395:Catecholamines / Q000037:antagonists & inhibitors; D002415:Cats; D003331:Coronary Vessels; D004074:Digitoxin / Q000037:antagonists & inhibitors; D004285:Dogs; D004357:Drug Synergism; D004562:Electrocardiography; D004837:Epinephrine / Q000494:pharmacology; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D007545:Isoproterenol / Q000037:antagonists & inhibitors; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009206:Myocardium / Q000032:analysis; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D010101:Oxygen Consumption / Q000187:drug effects; D010455:Peptides / Q000633:toxicity; D011433:Propranolol / Q000494:pharmacology; D011437:Propylamines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D011955:Receptors, Drug; D013565:Sympatholytics / Q000494:pharmacology*
D000605:Amino Alcohols; D000779:Anesthetics, Local; D002395:Catecholamines; D008996:Monoamine Oxidase Inhibitors; D010455:Peptides; D011437:Propylamines; D011955:Receptors, Drug; D013565:Sympatholytics; D011433:Propranolol; D004074:Digitoxin; D007545:Isoproterenol; D009638:Norepinephrine; D004837:Epinephrine
Pharmakologische Untersuchungen mit 1-Isopropylamono-3-(o-allyloxyphenoxy)-2-propanol-hydrochlorid, einem adrenergischen beta-Receptorenblocker.